CN114828961B - 通过阿片类己二烯酸酯和任选取代的己二烯酸酯增强阿片受体结合的组合物及方法 - Google Patents
通过阿片类己二烯酸酯和任选取代的己二烯酸酯增强阿片受体结合的组合物及方法 Download PDFInfo
- Publication number
- CN114828961B CN114828961B CN202080071185.9A CN202080071185A CN114828961B CN 114828961 B CN114828961 B CN 114828961B CN 202080071185 A CN202080071185 A CN 202080071185A CN 114828961 B CN114828961 B CN 114828961B
- Authority
- CN
- China
- Prior art keywords
- opioid
- nalbuphine
- naloxone
- compound
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885311P | 2019-08-11 | 2019-08-11 | |
| US62/885,311 | 2019-08-11 | ||
| US16/540,058 | 2019-08-14 | ||
| US16/540,058 US11186585B2 (en) | 2018-08-17 | 2019-08-14 | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
| PCT/US2020/021599 WO2021029914A1 (en) | 2019-08-11 | 2020-03-07 | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114828961A CN114828961A (zh) | 2022-07-29 |
| CN114828961B true CN114828961B (zh) | 2024-03-29 |
Family
ID=74571142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080071185.9A Active CN114828961B (zh) | 2019-08-11 | 2020-03-07 | 通过阿片类己二烯酸酯和任选取代的己二烯酸酯增强阿片受体结合的组合物及方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4010078A4 (https=) |
| JP (1) | JP7535569B2 (https=) |
| CN (1) | CN114828961B (https=) |
| CA (1) | CA3149152A1 (https=) |
| MX (1) | MX2022001520A (https=) |
| WO (1) | WO2021029914A1 (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017091827A1 (en) * | 2015-11-29 | 2017-06-01 | Thottathil John K | Novel alpha-hydroxy carboxylic acid and derivatives and other gras based prodrugs of oxycodone and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4668685A (en) | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
| EP0615756B1 (en) * | 1993-03-15 | 2001-06-27 | National Science Council | Nalbuphine esters and long-acting pharmaceutical compositions containing them |
| CN1050130C (zh) | 1997-07-04 | 2000-03-08 | 卢正堂 | 纳洛酮酸脂和纳屈酮酸脂及系列物和制备方法 |
| DE60001487T2 (de) | 2000-04-27 | 2003-12-24 | Oliver Yoa-Pu Hu | Polynalbuphinderivat |
| TWI226239B (en) | 2000-05-15 | 2005-01-11 | You-Pu Hu | Novel oral pharmaceutical composition containing nalbuphine ester prodrug |
| EP1309354A2 (en) | 2000-07-27 | 2003-05-14 | Rutgers, The State University | Therapeutic polyesters and polyamides |
| US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
| US20040033253A1 (en) | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
| WO2005009377A2 (en) | 2003-07-23 | 2005-02-03 | University Of Kentucky Research Foundation | Novel oral bioavailable prodrugs |
| US20050137141A1 (en) | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
| US8163701B2 (en) | 2005-08-19 | 2012-04-24 | Signature Therapeutics, Inc. | Prodrugs of active agents |
| US20090192095A1 (en) | 2008-01-18 | 2009-07-30 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
| BRPI1015108A2 (pt) | 2009-04-02 | 2016-04-26 | Shire Llc | pró-fármacos de aminoácidos e peptídios ligados a ácido dicarboxílico de opiáceos e seus usos |
| WO2011007247A1 (en) | 2009-07-17 | 2011-01-20 | Llc Shire | Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
| MX2012000980A (es) | 2009-07-21 | 2012-06-12 | Nektar Therapeutics | Conjugados de agonistas de oligómeros-opioides. |
| US20110190267A1 (en) * | 2010-01-05 | 2011-08-04 | Shire Pharmaceuticals, Inc. | Prodrugs of opioids and uses thereof |
| US8461171B2 (en) | 2010-02-09 | 2013-06-11 | QRxPharma Ltd. | Hybrid opioid compounds and compositions |
| CA2795156C (en) * | 2010-04-02 | 2019-05-14 | Alltranz Inc. | Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs |
| EP2658523A1 (en) | 2010-12-28 | 2013-11-06 | Euro-Celtique S.A. | A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease |
| US10449190B2 (en) | 2015-04-27 | 2019-10-22 | John K. Thottathil | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof |
| US9987269B2 (en) | 2015-04-27 | 2018-06-05 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof |
| CN107427509B (zh) * | 2015-08-29 | 2021-06-15 | 美德阿利克斯株式会社 | 含有碱性药物和山梨酸的经皮吸收组成物 |
| US12590065B2 (en) | 2017-04-14 | 2026-03-31 | Zevra Therapeutics, Inc. | Levorphanol prodrugs and processes for making and using them |
| US11186585B2 (en) * | 2018-08-17 | 2021-11-30 | Kappa-Pharma LLC | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
-
2020
- 2020-03-07 CA CA3149152A patent/CA3149152A1/en active Pending
- 2020-03-07 JP JP2022509137A patent/JP7535569B2/ja active Active
- 2020-03-07 EP EP20852037.9A patent/EP4010078A4/en active Pending
- 2020-03-07 WO PCT/US2020/021599 patent/WO2021029914A1/en not_active Ceased
- 2020-03-07 MX MX2022001520A patent/MX2022001520A/es unknown
- 2020-03-07 CN CN202080071185.9A patent/CN114828961B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017091827A1 (en) * | 2015-11-29 | 2017-06-01 | Thottathil John K | Novel alpha-hydroxy carboxylic acid and derivatives and other gras based prodrugs of oxycodone and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022544564A (ja) | 2022-10-19 |
| WO2021029914A1 (en) | 2021-02-18 |
| CN114828961A (zh) | 2022-07-29 |
| MX2022001520A (es) | 2022-07-21 |
| CA3149152A1 (en) | 2021-02-18 |
| EP4010078A1 (en) | 2022-06-15 |
| EP4010078A4 (en) | 2023-08-09 |
| JP7535569B2 (ja) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11851439B2 (en) | Compositions and methods of use for opioid hexadienoates and optionally substituted hexadienoates | |
| CA2448665C (en) | Sustained-release analgesic compounds | |
| EP1603597B1 (en) | Oxycodone conjugates with lower abuse potential and extended duration of action | |
| CN102480959B (zh) | 氢可酮的苯甲酸缀合物、苯甲酸衍生物缀合物和杂芳基羧酸缀合物及其前药、制备方法和用途 | |
| US20110190267A1 (en) | Prodrugs of opioids and uses thereof | |
| AU2002305816A1 (en) | Sustained-release analgesic compounds | |
| KR20140089520A (ko) | 히드로모르폰의 벤조산, 벤조산 유도체 및 헤테로아릴 카르복실산 컨쥬게이트, 전구약물, 이의 제조 방법 및 용도 | |
| EP3355885B1 (en) | Polysubunit opioid prodrugs resistant to overdose and abuse | |
| CA2781436C (en) | Arachidonic acid analogs and methods for analgesic treatment using same | |
| WO2007075883A9 (en) | Transdermal delivery of meptazinol | |
| CN102711759B (zh) | 胆道疾病的治疗或预防药 | |
| EP1782834A2 (en) | Oxycodone conjugates with lower abuse potential and extended duration of action | |
| JP7830540B2 (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| US8710069B2 (en) | Opioid-nornicotine codrugs combinations for pain management | |
| WO2021178691A1 (en) | Ibogaine analogs as therapeutics for neurological and psychiatric disorders | |
| CN114828961B (zh) | 通过阿片类己二烯酸酯和任选取代的己二烯酸酯增强阿片受体结合的组合物及方法 | |
| TWI356826B (https=) | ||
| CN106999487A (zh) | 羟吗啡酮的苯甲酸缀合物、苯甲酸衍生物缀合物和杂芳基羧酸缀合物、其前药、制备和使用方法 | |
| WO2020159565A1 (en) | Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent | |
| US20170217976A1 (en) | 6-(amino acid)-morphinan derivatives in combination with permeation enhancers for use as an orally, rectally, transdermally or nasally administered medicament | |
| EP4087575A1 (en) | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor | |
| WO2020159588A1 (en) | Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent | |
| US8557784B2 (en) | Glycyrrhizinates of morphinan derivatives | |
| WO2025216797A1 (en) | Dosing of polysubunit opioid prodrugs resistant to overdose and abuse | |
| CN101898977A (zh) | Gaba偶合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |